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Background: Congenital chloride diarrhea (CLD) is an autosomal recessive disorder characterized by life-long,
severe diarrhea with intestinal Cl- malabsorption. It results from a reduced activity of the down regulated in adenoma
exchanger (DRA), due to mutations in the solute carrier family 26, member 3 (SLC26A3) gene. Currently available
therapies are not able to limit the severity of diarrhea in CLD. Conflicting results have been reported on the
therapeutic efficacy of oral butyrate.
Methods: We investigated the effect of oral butyrate (100 mg/kg/day) in seven CLD children with different
SLC26A3 genotypes. Nasal epithelial cells were obtained to assess the effect of butyrate on the expression of the
two main Cl- transporters: DRA and putative anion transporter-1 (PAT-1).
Results: A variable clinical response to butyrate was observed regarding the stool pattern and fecal ion loss.
The best response was observed in subjects with missense and deletion mutations. Variable response to
butyrate was also observed on SLC26A3 (DRA) and SLC26A6 (PAT1) gene expression in nasal epithelial cells of
CLD patients.
Conclusions: We demonstrate a genotype-dependency for butyrate therapeutic efficacy in CLD. The effect of
butyrate is related in part on a different modulation of the expression of the two main apical membrane Cl- exchangers
of epithelial cells, members of the SLC26 anion family.
Trial registration: Australian New Zealand Clinical trial Registry ACTRN12613000450718.
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Congenital chloride diarrhea (CLD-OMIM 214700) is an
autosomal recessive disorder characterized by life-long,
severe diarrhea with intestinal Cl- malabsorption. It re-
sults from a reduced activity of the down-regulated in
adenoma exchanger (DRA), due to mutations in the sol-
ute carrier family 26, member 3 (SLC26A3) gene [1-3].
In humans, SLC26A3 encodes for a 764-amino acid pro-
tein and is located on chromosome 7 in a head-to-tail
arrangement with SLC26A4 (pendrin), indicating ancient* Correspondence: berni@unina.it
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reproduction in any medium, provided the orgene duplication [1-3]. Over 50 different SLC26A3 muta-
tions, including founder mutations in Finland, Poland,
Saudi Arabia and Kuwait populations, have been identi-
fied in CLD patients [4]. Such mutations are heteroge-
neous (mainly missense, insertion/deletion, nonsense
and splicing), spread all over the SLC26A3 gene, and
have a different impact on the expression and the activ-
ity of DRA [5,6]. Although no genotype-phenotype cor-
relation attributed to different SLC26A3 mutations has
been noted, the overall clinical picture and outcome of
CLD patients range from severe neonatal disease, with
life threatening hypoelectrolytemia and dehydration, to a
relatively mild chronic form, which may remain undiag-
nosed for long time [7-10]. Increasing evidences suggest
the importance of early diagnosis and treatment, and of
other undefined environmental factors, as modulators ofLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tients with CLD, supplementation therapy with a com-
bination of Cl- salts (NaCl and KCl) is essential in
preventing episodes of dehydration that could result in
mental and psychomotor impairment, and in chronic
contraction of the intravascular space that could lead to
renal dysfunction and gout [7,11]. Unfortunately, this
therapy is unable to limit the severity of diarrhea, as for
other therapeutic approaches, such as omeprazole, acet-
azolamide and cholestyramine [12-15].
The role of the amylase-resistant starch has been in-
creasingly recognized for the management of diarrheal
diseases [16,17]. Dietary fibres are fermented by gut
microbiota into short-chain fatty acids (SCFAs), includ-
ing acetate, propionate, and butyrate [18-20]. Butyrate
exerts a powerful pro-absorptive stimulus on intestinal
NaCl transport and an anti-secretory effect on Cl- secre-
tion [2,19,20]. In a child affected by CLD, we demon-
strated the therapeutic efficacy of oral butyrate, showing
a progressive reduction to normal values in the number
of bowel movements and stool volume, an improvement
in stool consistency, and a reduction of fecal incontin-
ence episodes. A reduction of fecal electrolyte and per-
sistency of normal serum electrolyte concentrations were
also demonstrated [18]. Subsequently, Wedenoja et al. evi-
denced different results in five CLD patients homozygous
for a frameshift mutation [21]. These findings suggest that
the variable response to butyrate could depend, at least in
part, on different SLC26A3 genotype.
The two main transporters involved in Cl- absorption
at intestinal level are DRA and putative anion trans-
porter 1 (PAT-1), encoded by SLC26A6 gene [22]. It has
been demonstrated that butyrate is able to regulate DRA
gene expression in intestinal epithelial cells [22], but the
possible effect of butyrate on SLC26A3 and SLC26A6 ex-
pression in CLD patients is still unknown.
In this study we evaluated the therapeutic effect of butyr-
ate in children affected by CLD with different SLC26A3
genotype through a clinical trial and an in vitro investigation.
Methods
Clinical trial
Ethics
The study protocol was approved by the Ethics Committee
of the University of Naples Federico II (n. 3469/07) and
by the Italian Agency for Drugs (AIFA), and it was
registered in the Australian New Zealand Clinical trial
Registry (ACTRN12613000450718). All authors had ac-
cess to the study data and had reviewed and approved
the final manuscript.
Population
The Pediatric Gastroenterology Unit at the University of
Naples “Federico II” is an International Reference Centerfor patients with CLD, and served as Coordinator Center
of this study. From 2005 to 2010, 35 cases of suspected
CLD were referred to the Center, and a definitive diag-
nosis of CLD was obtained in 25 patients with different
ethnicity. Demographic, clinical and laboratory data of
all CLD patients were collected in a dedicated data-base.
All subjects included in this database were invited to
participate in the study with the aim to evaluate at least
one patient for each of main mutations (missense, de-
letion, nonsense and splicing). The physicians of all
Centers received by E mail the protocol and any re-
quest of information was satisfied by a direct contact
with the Coordinator Center. Exclusion criteria were:
severe dehydration; concomitant presence of infec-
tions; concomitant other chronic diseases; renal insuf-
ficiency; use of probiotics/prebiotics, non-steroideal
anti-inflammatory drugs (NSAIDs), or antibiotics in
the last 4 weeks.
Genotype definition of children enrolled into the clinical
trial
Molecular analysis was performed in the laboratory of
CEINGE-Biotecnologie Avanzate , the reference Center
for molecular diagnosis of inherited diseases in Campania
region (about 6 million of inhabitants), located in southern
Italy. DNA was extracted from an EDTA blood sample
with the Nucleon BACC2 kit (Amersham Biosciences,
USA). The primers used are reported elsewhere [23]. The
touchdown PCR protocol that enables co-amplification
of all exons under the same PCR conditions is available
on request. Sequencing analysis was carried out on
both strands with an automated procedure (3100
Genetic Analyzer, Applied Biosystem). All PCR frag-
ments were sequenced with the primers used for PCR.
Furthermore, we used the Expand Long Template PCR
System (Roche, Germany) to verify deletion extension
in patient bearing c.2008-151_2061 + 1546 del muta-
tion. We used the forward primer of exon 17 and the
reverse primer of exon 19 [23], both known to be
intact in exon-specific assays. The expected fragment
is about 6300 bp. The PCR conditions are available on
request.
Intervention
We used a commercially available sodium butyrate for-
mulation (SOBUTIR®, Promefarm, Milan, Italy). Butyrate
was administered orally at 100 mg/kg/day, divided in 2
doses, with a maximal dosage of 4 g/day, for 1 week.
Number of tablets of sodium butyrate (1 gr/tablet) con-
sumed by the child during the trial were reported in a
specific form by the parents. A good compliance was
considered the intake of at least 80% of the prescribed
doses. Parents of the enrolled children were advised to
avoid co-administration of other treatments, including
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during the trial. Children continued their normal diet
during the study period. Throughout the study period,
all CLD subjects were examined as outpatients and they
had free access to the services of referred hospitals.
Trial design and data collection
This was an open trial on subjects with a confirmed
diagnosis of CLD. The purposes and the modalities of
the study were illustrated to the parents during the first
visit (Visit 1), and a written informed consent was ob-
tained from parents or tutors of each enrolled patient.
Baseline clinical and laboratory data were collected dur-
ing the week before butyrate treatment, and were con-
sidered representative of the usual pattern of each
enrolled patient. In particular, the parents of each pa-
tient were instructed to record daily in a specific clinical
chart: number of bowel movements, fecal volume, stool
consistency (using a scoring system: normal = 0, loose = 1,
semi-liquid = 2, liquid =3), and presence of incontinence.
At the end of the baseline week of observation, the clinical
chart of each child was collected and the patient was re-
evaluated (Visit 2). A full clinical evaluation was per-
formed and serum, fecal and urinary ion concentrations
were determined, together with serum pH, renin and al-
dosterone values, as previously described [18]. Fecal elec-
trolyte concentrations were measured on stool samples
collected daily during the last 3 days of observational
period. The parents of each enrolled subject received a
written prescription about the modalities of butyrate ad-
ministration for 1 week associated with oral NaCl/KCl
supplementation, as previously described [18]. In the last
3 days of treatment we collected daily a fecal sample to
study the effect of butyrate on fecal Na+ and Cl- concen-
tration. At the end of treatment with butyrate, the patients
were re-evaluated (Visit 3), and serum, urinary and fecal
electrolyte concentrations were measured again. Primary
outcome of the study was the reduction of Cl- and Na+
fecal losses induced by butyrate therapy.
In vitro study
Ex-vivo epithelial cell collection by nasal brushing
Nasal brushing was performed using an endo-brush at
the level of the inferior turbinate without anesthetic
procedures.
Epithelial cell culture
The sample obtained from each nostril was immediately
conserved in a 15 mL tube containing 2.5 mL of RPMI
1640 medium, complemented with 3% ampicillin. Cells
were placed on Eppendorf Thermomixer, in agitation at
300 rpm for one hour. Once removed the brush from
every sample, cells were centrifuged at 931 Xg (2000 rpm)
for 20 minutes, supernatant was discarded and cell pelletwas treated with 150 μL of Trypsin-Versene (EDTA) solu-
tion (Lonza, SW) for 4 minutes at 37°C, in order to disag-
gregate possible cell clusters. Trypsin was inactivated by
adding 3 mL of serum-free Bronchial Epithelial cell
Growth Medium (BEGM Clonetics, USA). After centrifu-
gation at 2000 rpm for 10 minutes, cells were placed in
CELL + T 25 flasks (Sarstedt Ltd, UK). At confluence of
60%, cells were passed in new flasks after count using
Invitrogen Cell Countess (Invitrogen, UK). Trypan blue
exclusion test was used in order to establish total viable
cells number and percentage of viability.Effect of butyrate on epithelial cells
At the confluence of >80%, cells were treated with
5 mM of sodium butyrate for 24 hours. RNA was ex-
tracted with TRIZol method (Invitrogen, UK). Total
RNA amount was quantified with Nanodrop 1000 spec-
trophotometer (Thermo Fisher Scientific, UK). One
microgram of total RNA was retro-transcribed with
Quantitect Reverse Transcription kit (Qiagen, Germany),
cDNA was diluted for downstream applications like
quantitative real-time PCR analysis. Expression levels of
either SLC26A3 and SLC26A6 from treated and un-
treated cells were measured by semi-quantitative real-
time PCR on LightCycler 480 Real-Time PCR System
(Roche, Germany) with Taqman probe chemistry (exper-
iments were performed in replicate using also SYbr
Green chemistry). Results were normalized for house-
keeping glyceraldheyde 3-phosphate dehydrogenase
(GAPD) gene. Levels of SLC26A3 and SLC26A6 expres-
sion before and after treatment were compared in order
to establish changes determined by butyrate exposure.
Calculation of relative gene expression was performed
according to Pfaffl et al. [24], and the expression was cal-
culated using the formula of relative gene expression
with DDCt method (where DDCt corresponds to the in-
crease in the threshold cycle of the target gene with re-
spect to the increase in the threshold cycle of the
housekeeping gene). Hence, the final quantification value
for each condition indicated the relative change of gene
expression in the target gene compared to the control,
for each sample.Statistical analysis
The Kolmogorov-Smirnov test was used to determine
whether variables were normally distributed. The chi-
square test was applied for categorical variables, and for
continuous variables, differences between groups were
analyzed by Mann- Whitney U test, and Kruskal-Wallis
H test. A multivariate analysis was performed to evaluate
if the effects of butyrate may depend by clinical or
genetic factors. All analyses were conducted on an
intention-to-treat (ITT) basis. Statistical analysis was
Assessed for eligibility (n=25  )
Excluded  (n=18)
¨ Not meeting inclusion criteria (n=8)
¨ Declined to participate (n=10)
Analysed  (n=7 )
Allocated to intervention (n=7)
¨ Received allocated intervention (n=7)Allocation
Analysis
Eligibility
Enrollment Enrolled (n=7)
Figure 1 Flow diagram of the study (according to CONSORT guidelines).
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and by StatDirect 1.7.
Results
Clinical trial
Enrollment of patients was performed from January
2010 to December 2012. Out of 25 eligible children with
CLD, 18 subjects were excluded (8 not meeting inclusion
criteria, 10 declined to participate because differentTable 1 Main demographic characteristics and genotype of p
Patient Age at diagnosis Age the enrollment Sex Ethnic origin
1 6.5 y 16 y M Caucasian
2 4 m 3 y M Caucasian
3 6 y 12 y M Caucasian
4 3 m 18 y F Caucasian
5 1 m 18 y M African
6 1 m 15 y M African
7 10 m 1.5 y M Caucasian
*Novel mutations.Ethics Committee regulatory procedures and logistic
difficulties), 7 were enrolled in the study (Figure 1). All
patients showed a typical clinical picture of CLD with
early onset diarrhea. Three subjects received a late
diagnosis.
SLC26A3 genotype was defined for each subjects. Pa-
tients 1, 3 and 7 presented previously unreported muta-
tions. Patients 1 and 2 had missense mutations and the
protein was expressed on cell membrane. Patient 3 wasatients with congenital chloride diarrhea
Body weight (kg) SLC26A3 genotype Type of mutation
70 c.1484A > C* Missense
c.1640C > A*
22 c.386C > T Missense
c.386C > T
32 c.1008-151_2061 + 1546del* Deletion
c.1008-151_2061 + 1546del*
58 c.2132 T > G Nonsense
c.2132 T > G
55 c.559G > T Nonsense
c.559G > T
57 c.559G > T Nonsense
c.559G > T
10 c.1408-G > C* Splicing
c.1408-G > C*
Basal
Butyrate
Patients
P<0.001 P<0.001 P<0.001 P<0.001
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Figure 2 Fecal sodium (a) and chloride concentration (b) in children with congenital chloride diarrhea treated with butyrate. Box and
bar represent median and min-max range, respectively.
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of a truncated protein and some amount of the protein
was present at membrane level. Patients 4 to 6 were
homozygous for nonsense mutations with no protein
expression at membrane level. Patient 7 was homozygous
for a splicing mutation that causes the synthesis of an
aberrant mRNA, with no protein expression at membrane
level. The genotype and main demographic features of
study subjects are reported in Table 1.
All patients were evaluated in stable clinical condi-
tions. Overall, butyrate therapy induced a reduction of
Cl- (136 mmol/l, IQR 13 vs 120 mmol/l, IQR 42;Table 2 Effects of butyrate on daily stool pattern in patients
Patient Bowel movements Stool volume (
Basal On Butyrate p Basal
1 4 (3) 2 (1) 0.003 2100 (500)
(3–6) (2–3) (1800–2300)
2 4 (2) 3 (1) 0.147 1400 (450)
(3–5) (3–4) (1200–1650)
3 3 (2) 2 (0) 0.021 1500 (200)
(2–4) (2–2) (1400–1600)
4 6 (2) 6 (1) 0.892 2000 (400)
(5–7) (6–7) (1800–2200)
5 2 (2–3) 2 (1) 0.263 1200 (200)
(2–3) (1–2) (1100–1300)
6 2 (2) 1 (0) 0.238 900 (200)
(0–2) (1–1) (800–1000)
7 3 (1) 4 (1) 0.299 1000 (200)
(3–4) (3–4) (900–1100)
Note. Data are expressed as median (interquartile range). Stool consistency score: np < 0.001) and Na+ (78 mmol/l, IQR 29 vs 50 mmol/l,
IQR 49; p = 0.002) fecal losses in CLD patients, but a
variable response was observed in children with different
SLC26A3 genotype. The more evident reduction of fecal
ion losses was observed in patients with missense and de-
letion mutations (Figure 2).
A variable clinical response was also observed on stool
pattern in CLD patients with different mutations. Clinical
response (defined by a concomitant significant reduction
of ≥2 variables) was observed in patients with missense
and deletion mutations (Table 2). A reduction of incon-
tinence episodes was observed in patients 1, 2 and 3.with congenital chloride diarrhea
ml) Stool consistency (score)
On Butyrate p Basal On Butyrate p
1600 (450) 0.047 3 (2) 2 (1) 0.379
(1400–1850) (1–3) (2–2)
1200 (300) 0.046 3 (0) 2 (1) 0.023
(1000–1300) (3–3) (2–3)
900 (400) 0.015 3 (0) 2 (1) 0.107
(800–1200) (3–3) (2–3)
1500 (200) 0.053 3 (0) 2 (1) 0.037
(1500–1700) (3–3) (2–3)
1100 (300) 0.261 2 (1) 3 (1) 0.606
(900–1200) (2–3) (2–3)
800 (400) 0.435 2 (1) 2 (1) 0.872
(700–1100) (1–2) (1–2)
900 (200) 0.289 2 (1) 2 (0) 0.254
(800–1000) (1–2) (2–2)
ormal = 0, loose = 1; semi-liquid = 2; liquid = 3.
Table 3 Effects of butyrate on fecal electrolytes loss and on stool pattern, according to variation of genotype in
patients with congenital chloride diarrhea
Genotype Response to butyrate
Patient SLC26A3 genotype Type of mutation Fecal Cl- loss Stool Pattern*
1 c.1484A > C* Missense Reduced Improved
c.1640C > A*
2 c.386C > T Missense Reduced Improved
c.386C > T
3 c.1008-151_2061 + 1546del* Deletion Reduced Improved
c.1008-151_2061 + 1546del*
4 c.2132 T > G Nonsense Unchanged Unchanged
c.2132 T > G
5 c.559G > T Nonsense Unchanged Unchanged
c.559G > T
6 c.559G > T Nonsense Unchanged Unchanged
c.559G > T
7 c.1408-G > C* Splicing Unchanged Unchanged
c.1408-G > C*
*defined as a significant reduction of a least two out of three parameters (bowel movements, stool volume, stool consistency).
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within the first 48 hours and remained stable during the
following days of treatment.
The multivariate analysis revealed that only the geno-
type significantly (p = 0.008) influence the response to
butyrate treatment (i.e. missense and deletion mutations
that allow the expression of DRA at membrane level).
The study procedures and oral butyrate treatment were
well accepted by the patients. Serum and urinary elec-
trolyte concentrations, and serum pH, renin and aldos-
terone levels remained stable within normal ranges
during the study period. In Table 3 were summarized
the main results of butyrate therapy according to the
type of mutations observed in CLD patients.
In vitro study
A variable response to butyrate was observed on SLC26A3
mRNA expression in epithelial nasal cell culture. Butyrate
was able to increase the expression of SLC26A3 gene in 5
out of 7 CLD patients (i.e., patients 1, 2, 3, 4 e 7). In two
cases (i.e., patients 5 and 6, both homozygous for the
G187X nonsense mutation) butyrate significantly inhibited
SLC26A3 expression (Figure 3). The SLC26A6 mRNA
expression resulted significantly increased by butyrate in
epithelial nasal cells from 5 out of 7 CLD patients, i.e., cases 2,
4, 5, 6 and 7, while it was significantly reduced in one case
(i.e., patient 1) and remained unchanged in patient 3 (Figure 3).
Discussion
This is the first study exploring the efficacy of butyrate
in a population of CLD subjects with different mutationsin SLC26A3 gene. We confirm the efficacy of butyrate
on intestinal ion transport in a subset of CLD patients
and we demonstrate that the clinical effect of butyrate is
at least in part dependent on genotype. A full response
to butyrate (defined by a concomitant significant re-
duction of Na+ and Cl- fecal losses and improvement in
stool pattern) was observed only in patients with
missense and deletion mutations. On the contrary, a
partial response was observed in patients with nonsense
or splicing mutations.
It has been previously demonstrated that butyrate is
able to modulate transepithelial ion transport through at
least 2 mechanisms: i) stimulation of Na+/H+ exchangers
2 (NHE2) and 3 (NHE3) activity; ii) inhibition of Cl-
secretion by limiting the action of the co-transporter
Na-K-2Cl (encoded by NKCC1) on enterocyte baso-
lateral membrane [19]. It has been shown that butyrate
stimulates DRA expression in LS174T colonic cells
[25], whenever data on a possible activity on PAT-1
gene expression were unavailable. Now we demon-
strate that, in CLD patients, butyrate is able to modu-
late the expression of the two main intestinal Cl-
transporters: DRA and PAT1. The effect elicited on
these two transporters could be considered a third
potential mechanism of action, and it could be in-
volved in the genotype-dependency of butyrate effect
in CLD patients. The effect of butyrate on these two
transporters seems to be different according to the
type of SLC26A3 mutation. Patients with non-sense or
splicing mutations showed a lower response in SLC26A3,
but a more pronounced increase in SLC26A6 mRNA
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Figure 3 SLC26A3/DRA mRNA and SLC26A6/PAT-1 mRNA expression in epithelial cells of children enrolled into the trial before and
after in vitro stimulation with butyrate. *p < 0.05 vs. basal.
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mutation showed a more pronounced increase in
SLC26A3 expression and a lower effects on SLC26A6
mRNA expression in nasal epithelial cell culture. Inter-
estingly, a 3-fold up-regulation of PAT-1 expression
was detected in DRA-knockout mice [26]. Altogether,
these findings suggest that the up-regulation of PAT-1
in CLD patients may play a compensatory role in elec-
trolyte homeostasis. DRA has been shown to be the
major apical Cl- absorbing isoform in the colon and
ileum able to regulate a large amount of water daily
[25]. Additionally, studies have shown that DRA-
knockout mice show reduction in apical Cl-/HCO3 ex-
change activity and exhibit diarrheal phenotype with
significant increased Cl- and water stool content [25].
On the contrary, although PAT-1 is involved in Cl-
transport, unlike DRA it is not directly coupled to the
water movements demonstrated by PAT-1-knockout
mice showing a reduction in Cl- absorption, but not
exhibiting a diarrheal phenotype [26,27]. Thus it is
possible to hypothesize that the effect induced by bu-
tyrate on fecal ions loss is due at least in part by a
regulatory action on PAT-1 expression.
The variable butyrate effect in CLD patients seems to
be influenced by SLC26A3 genotype. However, the dif-
ferent diarrhea-reducing responses of butyrate observed
among patients with similar mutations strongly suggests
the existence of other still unidentified regulatory ele-
ments. The hypothesis that butyrate may display a large
pattern of biochemical effects on intestinal ion channels
with a strong inter-individual variability is also sup-
ported by a study on 5 CLD patients, all homozygousfor a deletion mutation, showing a variable clinical re-
sponse to this treatment [21].
We feel that the evidence of an improved clinical out-
come by butyrate at least in a subset of CLD patients is
of potential importance either for the therapeutic man-
agement and for the interpretation of the mechanisms
that regulate ion absorption at intestinal level in this
condition. The effects of endogenous production of bu-
tyrate elicited by different dietary habits could be able to
influence the clinical picture in CLD patients with same
genotype, as previously reported [19].
Conclusion
We demonstrate that butyrate may act efficiently on ei-
ther fecal ion loss, and on the severity of diarrhea in a
subset of CLD patients. The activity of butyrate seems to
be more complex than expected, depending either on
the profile of the SLC26A3 gene mutations, but also on
other genes, and our study starts to make light on this
network.
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